Empasiprubart by IV for adults with Multifocal Motor Neuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, open-label study administers empasiprubart intravenously to adults with MMN to examine its effects on nerve thickness, muscle strength, movement, and grip ability. Participants receive the treatment over a defined period, followed by a safety follow-up of up to 15 months, with an overall involvement of about 29 months per participant. Outcomes focus on ultrasound-determined nerve morphology, functional strength, and daily-hand use. The trial is sponsored by argenx and conducted at selected clinics in Tbilisi, Georgia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Is at least 18 years old
* Diagnosed with MMN
* Has an MMN-RODS centile score of ≤90
* Has confirmed nerve thickening in at least 1 nerve per ultrasound measurement

Exclusion Criteria:

* Besides the indication under study, known autoimmune disease or any medical condition that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of MMN or puts the participant at undue risk.

Where it's running

• Pineo Medical Ecosystem
  Tbilisi, K'alak'i T'bilisi, Georgia Recruiting
• Aversi Clinic LTD
  Tbilisi, Georgia Recruiting
• Jo Ann Medical Center
  Tbilisi, Georgia Recruiting
• S. Khechinashvili University Clinic, Ltd.
  Tbilisi, Georgia Recruiting

Study contacts

• Study coordinator: Sabine Coppieters, MD
• Email: clinicaltrials@argenx.com
• Phone: 857-350-4834

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How ARGX-121 affects protein in IgA nephropathy

  This study tests whether ARGX-121 can change protein in urine and other kidney outcomes in adults with IgA nephropathy.

  Recruiting at 10 sites Phase 2 argenx · Valencia, California and 10 other locations · NCT07773727

• Empasiprubart IV in people with AChR-Ab positive generalized myasthenia gravis

  This study tests whether empasiprubart given by IV can help people with AChR-Ab positive generalized myasthenia gravis feel better and have fewer symptoms.

  Recruiting at 14 sites Phase 2 argenx · Carlsbad, California and 13 other locations · NCT07673627

• How Adimanebart Moves Through the Body in Healthy Adults

  This study tests how much adimanebart enters the blood and how it behaves in healthy adults after IV and SC dosing.

  Recruiting Phase 1 argenx · Montreal · NCT07673601

• Empasiprubart: how your body handles an autoinjector shot versus IV in healthy adults

  This study tests how empasiprubart behaves in the body when given as a subcutaneous autoinjector injections in the abdomen or thigh compared with IV, in healthy adults.

  Recruiting Phase 1 argenx · Mount Royal, Quebec · NCT07612020

• Efgartigimod for Graves’ Disease in Adults

  This study tests whether giving efgartigimod under the skin helps thyroid function and is safe for adults with Graves’ disease.

  Recruiting at 51 sites Phase 3 argenx · Aalst, Oost-Vlass and 50 other locations · NCT07596849

• Impact of efgartigimod on overall disease experience in adults with generalized myasthenia gravis in Italy

  This study looks at real-world use of efgartigimod in adults with generalized myasthenia gravis to see how it affects their daily symptoms and experiences.

  Recruiting at 30 sites argenx · Acquaviva delle Fonti and 29 other locations · NCT07595653

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.